Inovio Pharmaceuticals Inc has a consensus price target of $10.5, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, RBC Capital, and Oppenheimer on March 8, 2024, March 7, 2024, and January 25, 2024. With an average price target of $18.33 between Oppenheimer, RBC Capital, and Oppenheimer, there's an implied 31.05% upside for Inovio Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/08/2024 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | 185.92% | Oppenheimer | Hartaj Singh | $40 → $40 | Maintains | Outperform | Get Alert |
03/07/2024 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -21.37% | RBC Capital | Gregory Renza | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
01/25/2024 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -71.41% | Oppenheimer | Hartaj Singh | → $4 | Upgrade | Perform → Outperform | Get Alert |
01/04/2024 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -92.85% | JMP Securities | Roy Buchanan | → $12 | Initiates | → Market Outperform | Get Alert |
05/11/2023 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -85.7% | RBC Capital | Gregory Renza | → $24 | Reiterates | Sector Perform → Sector Perform | Get Alert |
03/02/2023 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -85.7% | RBC Capital | Gregory Renza | $36 → $24 | Maintains | Sector Perform | Get Alert |
11/09/2022 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
11/01/2022 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -85.7% | B of A Securities | Geoff Meacham | → $24 | Downgrade | Neutral → Underperform | Get Alert |
08/10/2022 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -78.56% | RBC Capital | Gregory Renza | $48 → $36 | Maintains | Sector Perform | Get Alert |
05/11/2022 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
03/02/2022 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -64.26% | RBC Capital | Gregory Renza | $72 → $60 | Maintains | Sector Perform | Get Alert |
01/21/2022 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -28.52% | B of A Securities | Geoff Meacham | $96 → $120 | Upgrade | Underperform → Neutral | Get Alert |
11/01/2021 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -57.11% | RBC Capital | Gregory Renza | $84 → $72 | Maintains | Sector Perform | Get Alert |
09/10/2021 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -42.82% | B of A Securities | Geoff Meacham | $108 → $96 | Downgrade | Neutral → Underperform | Get Alert |
06/24/2021 | INO | Buy Now | Inovio Pharmaceuticals | $13.99 | -35.67% | Jefferies | Kelechi Chikere | → $108 | Initiates | → Hold | Get Alert |
The latest price target for Inovio Pharmaceuticals (NASDAQ: INO) was reported by Oppenheimer on March 8, 2024. The analyst firm set a price target for $40.00 expecting INO to rise to within 12 months (a possible 185.92% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Inovio Pharmaceuticals (NASDAQ: INO) was provided by Oppenheimer, and Inovio Pharmaceuticals maintained their outperform rating.
The last upgrade for Inovio Pharmaceuticals Inc happened on January 25, 2024 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Inovio Pharmaceuticals Inc.
The last downgrade for Inovio Pharmaceuticals Inc happened on November 9, 2022 when Maxim Group changed their price target from N/A to N/A for Inovio Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inovio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inovio Pharmaceuticals was filed on March 8, 2024 so you should expect the next rating to be made available sometime around March 8, 2025.
While ratings are subjective and will change, the latest Inovio Pharmaceuticals (INO) rating was a maintained with a price target of $40.00 to $40.00. The current price Inovio Pharmaceuticals (INO) is trading at is $13.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.